Breast Cancer Ireland applauds this new breakthrough as Eli Lilly and Company has announced that its CDK4 & 6 inhibitor Verzenio (abemaciclib) has been found to significantly extend life in women with HR+, HER2- advanced breast cancer.

To read more about this, click the link below via Pharma Times.

http://www.pharmatimes.com/news/eli_lilly_announces_verzenio_survival_benefit_1295959?fbclid=IwAR1_QRfAIuOZ6HgZ6zzOEb5exIPc1l9v9h0WIrN8X1HkAX8d2HYbwW1GHi0